Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cue Biopharma Reports Second Quarter 2022 Financial Results Globe Newswire - Thu Aug 4, 2022

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.7225 (+0.21%)
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series Globe Newswire - Mon Jul 11, 2022

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.7225 (+0.21%)
Cue Biopharma to Present at the Jefferies Healthcare Conference Globe Newswire - Wed Jun 1, 2022

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.7225 (+0.21%)
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Thu May 26, 2022

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.7225 (+0.21%)
Cue Biopharma Reports First Quarter 2022 Financial Results Globe Newswire - Tue May 10, 2022

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.7225 (+0.21%)
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer Globe Newswire - Wed Jan 26, 2022

Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in...

CUE : 0.7225 (+0.21%)
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials Globe Newswire - Thu Jan 20, 2022

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.7225 (+0.21%)
Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer Globe Newswire - Wed Dec 15, 2021

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.7225 (+0.21%)
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference Globe Newswire - Mon Nov 22, 2021

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.7225 (+0.21%)
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November Globe Newswire - Wed Nov 10, 2021

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.7225 (+0.21%)

Barchart Exclusives

3 AI Stocks to Buy Instead of Super Micro Computer Barchart - Sat Aug 31, 7:30AM CDT
Following a significant drop in Super Micro Computer's stock due to a delayed 10-K filing and accounting concerns, investors are exploring alternative AI infrastructure stocks like Dell, Arista Networks, and Pure Storage, which offer strong growth prospects in the rapidly expanding AI market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot